What is the price target for SGTX stock?
9 analysts have analysed SGTX and the average price target is 48.28 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 22.47.
SIGILON THERAPEUTICS INC (SGTX) Forecast, Price Target & Analyst Ratings
NASDAQ:SGTX • US82657L2060
Current stock price
22.47 USD
-0.59 (-2.56%)
At close:
23 USD
+0.53 (+2.36%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SIGILON THERAPEUTICS INC (SGTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 8, 2023
- Period
- Q2 / 2023
- EPS Estimate
- -$4.81
- Revenue Estimate
- 4.335M
Price Target Details & History
Consensus Price Target and Range
Mean target
$48.28
Upside
+ 114.86%
From current price of $22.47 to mean target of $48.28, Based on 9 analyst forecasts
Low
$21.21
Median
$30.60
High
$95.55
Price Target Revisions
1 Month
0.00%
3 Months
1,013.72%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for SGTX. The average price target is 48.28 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 22.47.
The average price target has been revised upward by 1013.72% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
SGTX was analyzed by 9 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about SGTX.
In the previous month the buy percentage consensus was at a similar level.
SGTX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-07-05 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023-07-03 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-06-30 | BTIG | Downgrade | Buy -> Neutral |
| 2023-06-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-26 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-25 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-01-18 | Canaccord Genuity | Initiate | Buy |
| 2021-12-23 | Canaccord Genuity | Maintains | Buy |
| 2021-12-01 | Barclays | Maintains | Overweight |
| 2021-11-30 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-11-30 | Jefferies | Downgrade | Buy -> Hold |
| 2021-10-29 | BTIG | Initiate | Buy |
| 2021-07-19 | Canaccord Genuity | Maintains | Buy |
| 2021-07-16 | Morgan Stanley | Maintains | Equal-Weight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 8, 2023
- Period
- Q2 / 2023
- EPS Estimate
- -$4.81
- Revenue Estimate
- 4.335M
- Revenue Q2Q
- 50.36%
- EPS Q2Q
- -993.02%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
37.10%
EPS (1 Month)
0.21%
EPS (3 Months)
-1,950.00%
Next Earnings Summary
SGTX is expected to report earnings on 11/8/2023. The consensus EPS estimate for the next earnings is -4.81 USD and the consensus revenue estimate is 4.33M USD.
The next earnings revenue estimate has been revised upward by 37.1% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 13.374M -5.55% | 9.599M -28.23% | 12.944M 34.85% | 16.082M 24.24% | 16.32M 1.48% | 16.32M | 13.26M -18.75% | 13.26M | 13.26M | |
| EBITDA YoY % growth | -51.788M -19.22% | -74.518M -43.89% | -42.402M 43.10% | -33.274M 21.53% | -35.967M -8.09% | -35.967M | N/A | N/A | N/A | |
| EBIT YoY % growth | -52.642M -19.32% | -75.636M -43.68% | -43.666M 42.27% | -33.077M 24.25% | -37.479M -13.31% | -38.027M -1.46% | -44.268M -16.41% | -45.084M -1.84% | -45.798M -1.58% | |
| Operating Margin | -393.61% | -787.96% | -337.35% | -205.67% | -229.65% | -233.01% | -333.85% | -340.00% | -345.38% | |
| EPS YoY % growth | N/A | -2.43 95.31% | -7.11 -192.59% | -9.56 -34.47% | -13.12 -37.23% | -11.37 13.36% | -0.94 91.75% | -0.94 | -0.47 50.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|
| EPS Q2Q % growth | -4.81 -993.02% | -3.35 4.54% | -3.40 -24.60% |
| Revenue Q2Q % growth | 4.335M 50.36% | 4.335M 1.95% | 4.335M 63.96% |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.188M 41.66% | -8.418M 0.06% | -8.647M -11.86% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-16.93%
EPS Next 5 Year
13.31%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
6.68%
Revenue Next 5 Year
-0.28%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
8.16%
EBIT Next 5 Year
N/A
SIGILON THERAPEUTICS INC / SGTX Forecast FAQ
What is the next earnings date for SGTX stock?
SIGILON THERAPEUTICS INC (SGTX) will report earnings on 2023-11-08, after the market close.
Can you provide the consensus estimates for SIGILON THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of SIGILON THERAPEUTICS INC (SGTX) is -4.81 USD and the consensus revenue estimate is 4.33M USD.
What is the expected long term growth rate for SIGILON THERAPEUTICS INC (SGTX)?
The expected long term growth rate for SIGILON THERAPEUTICS INC (SGTX) is 6.68%.